SynthesisAdvances in therapy2022

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.

Raul Cordoba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.